Through the deal, BioDuro has acquired Molecular Response's translational oncology research platform and its biobank of viable tumor specimens.
Among other projects, the company will make improvements to its internal bioinformatics pipeline and develop a 5,000-sample cohort for oncology research use.
Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
The platform will be based on the company's BC|Rquest system for analyzing and viewing aggregated genomic and clinical data from multiple biobanks.
Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
Under the agreement MedStar will contribute to Indivumed’s biobank of annotated tumor and liquid biospecimen samples, and gain research access to this larger database.
TreeWAS provides a method for identifying gene variant-phenome associations in heterogenous biobank data without compromising phenotypic resolution.
The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.
The effort is already bearing fruit, as the team has been able to validate several variants known to be connected with adverse drug reactions.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.